HLS Therapeutics Inc.
4.33CAD
+0.1800 (+4.34%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on HLS.TO.
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 61.5M | 63.1M | 56.6M | 55.5M | 58.3M | 65.1M |
| Q1 | — | — | — | — | 12.9M | — |
| Q2 | — | — | — | 14.2M | 14.7M | — |
| Q3 | — | — | — | 13.5M | 14.9M | — |
| Q4 | — | — | — | 15.2M | 16.1M | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | -.730 | -.850 | -.620 | -.620 | -.207 | -.070 |
| Q1 | — | — | — | — | -.070 | — |
| Q2 | — | — | — | -.090 | -.030 | — |
| Q3 | — | — | — | -.120 | -.080 | — |
| Q4 | — | — |
Fiscal period: Reported, Estimated. Reported figures: Yahoo Finance (limited history). Estimates are sell-side consensus for periods that have not reported. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
Revenue to net income
| — |
| -.040 |
| -.040 |
| — |
Debt level and coverage